Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-02), EP Biocomposites's Beta is 0.4639.
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
EP Biocomposites Beta Related Terms
EP Biocomposites Beta Historical Data
* Premium members only.
The historical data trend for EP Biocomposites's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Building Products & Equipment subindustry, EP Biocomposites's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EP Biocomposites Beta vs Construction Industry
For the Construction industry and Industrials sector, EP Biocomposites's Beta distribution charts can be found below:
* The bar in red indicates where EP Biocomposites's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
EP Biocomposites (BOM:543595) has a Beta of 0.4639 as of Aug. 02, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for EP Biocomposites and its competitors.
Is EP Biocomposites' Beta too high?
EP Biocomposites' current Beta is 0.4639. Overall, EP Biocomposites has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EP Biocomposites' Beta compare to TT and JCI?
EP Biocomposites' Beta of 0.4639 can be compared against companies in the Construction industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Construction company?
A good Beta depends on the Construction industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for EP Biocomposites and its competitors. EP Biocomposites's current Beta is 0.4639. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EP Biocomposites stock overvalued right now?
Based on GuruFocus' analysis, EP Biocomposites (BOM:543595) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹201.91, compared to a current price of ₹106.00 — trading 47.5% below its estimated fair value. The current Beta is 0.4639. EP Biocomposites' overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For EP Biocomposites (BOM:543595), the current Beta is 0.4639 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EP Biocomposites (BOM:543595) Overvalued in 2026?
Based on GuruFocus' analysis, EP Biocomposites stock appears to be undervalued.
The current stock price of ₹106.00 is trading 47.5% below its estimated GF Value™ of ₹201.91.
GuruFocus considers EP Biocomposites to be Significantly Undervalued.
Key valuation signals for BOM:543595:
Beta: 0.4639
GF Value™: ₹201.91 vs. price of ₹106.00 (47.5% below fair value)
No single metric tells the full story. See the BOM:543595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EP Biocomposites Ltd is the manufacturer and supplier of fibre reinforced polymers products such as door shutters, frames, Biodigestor Tanks, Bio toilets and allied products for construction and Industrial applications. The company focus on giving sanitation solutions to those who do not have access to toilets, as well as to those who have toilets but face trouble treating and managing the waste through septic tanks. The company also provides sanitation infrastructure and human waste management solutions and services, involving simple bio-digester technology licensed from the Defence Research and Development Organisation (DRDO) and Industry Interface and Technology Management, operating under the aegis of DRDO, Ministry of Defence, Government of India.
76GF Score
Get the complete analysis for BOM:543595
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543595 has been successfully added to your 
